The use of chemoimmunotherapy in the first-line treatment of advanced small cell lung cancer: a case report and brief literature review
Yusupova Z.M., Muradova M.B., Zakharova A.M., Golubev P.V., Kuzmina E.S., Kuzmin V.M., Kachmasova A.K., Viderker S.P.
Background: Small cell lung cancer (SCLC) is a malignancy with an aggressive course and an extremely poor prognosis. In its advanced form, median survival rarely exceeds 12 months, even with chemotherapy. However, in recent years, the advent of immune checkpoint inhibitors (PD-L1 inhibitors), such as atezolizumab, has improved survival rates while maintaining acceptable toxicity.
Description of the clinical case: This case report presents the experience of treating a patient with disseminated small cell lung cancer. She achieved a significant positive response to combination chemoimmunotherapy (etoposide + carboplatin + atezolizumab) followed by maintenance therapy with an anti-PDL1 inhibitor. A brief overview of clinical trials on the efficacy of PD-L1 blockers in the treatment of SCLC is also provided.
Conclusion: The combination of immunotherapy and chemotherapy has become the standard of care for small cell lung carcinoma. The high efficacy of this combination was demonstrated in our clinical case.
For citations: Yusupova Z.M., Muradova M.B., Zakharova A.M., Golubev P.V., Kuzmina E.S., Kuzmin V.M., Kachmasova A.K., Viderker S.P. The use of chemoimmunotherapy in the first-line treatment of advanced small cell lung cancer: a case report and brief literature review. Pharmateca. 2025;32(9):185-189. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.9.185-189
Authors’ contribution: Kachmasova A.K., Viderker S.P., Kuzmin V.M. – collection of scientific data. Yusupova Z.M., Muradova M.B., Zakharova A.M. – data processing, article writing. Golubev P.V., Kuzmina E.S. – article editing.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: This study did not require additional funding.
Patient Consent for Publication: The patient provided an informed consent for the publication of their data.
Keywords
small cell lung cancer
immunotherapy
clinical case
atezolizumab
PD-L1
About the Authors
Zaina M. Yusupova, Student, Faculty of General Medicine, Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia; https://orcid.org/0009-0000-1328-766XMaryana B. Muradova, Student, Faculty of General Medicine, Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia; https://orcid.org/0009-0001-0512-7006
Alina M. Zakharova, Student, Faculty of General Medicine, Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia; https://orcid.org/0009-0001-8273-5582
Pavel V. Golubev, Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy, A.F. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Radiological Center, Obninsk, Russia; golubev194@gmail.com, https://orcid.org/0000-0003-3532-6476 (corresponding author)
Evgeniya S. Kuzmina, Cand. Sci. (Med.), Head of the Chemotherapy Department No. 2, Oncology Center No. 1, Yudin City Clinical Hospital, Moscow, Russia; https://orcid.org/0009-0007-2856-5176
Vladislav M. Kuzmin, Student, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; https://orcid.org/0009-0000-9658-3586
Abidat Kamilpashaevna Kachmasova, Oncologist, Chemotherapy Department No. 2, Oncology Center No. 1, Yudin City Clinical Hospital, Moscow, Russia; https://orcid.org/0009-0005-2365-495X
Svetlana P. Viderker, Oncologist, Chemotherapy Department No. 2, Oncology Center No. 1, Yudin City Clinical Hospital, Moscow, Russia; https://orcid.org/0009-0003-1025-4784
Similar Articles
